delta-9-tetrahydrocannabinol

PreclinicalSmall molecule

CCentre for Addiction and Mental Health

delta-9-tetrahydrocannabinol is one of 4 small molecule programs targeting Impairment. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImpairmentCompleted

ImpairmentPreclinical

Completed

Competition

Competitive Landscape

5 competitors in Impairment

#DrugCompanyPhaseTrials

LY3537031

Eli Lilly

Phase 1

1 2

Xe-133

NNobilis Therapeutics Inc.

Preclinical

1 3

Alcohol

Astellas

Preclinical

2 4

delta-9-tetrahydrocannabinol

CCentre for Addiction and Mental Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interaction2 trials

Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids

Completed·—·Phase 1·NCT02487381·60 enrolled

Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study

Withdrawn·—·Phase 1·NCT02492074

Cannabis1 trial

Cannabis Effects on Driving-related Skills of Young Drivers

Completed·CCentre for Addiction and Mental Health·N/A·NCT01592409·99 enrolled

Elderly1 trial

Safety and Tolerability of Namisol in the Elderly

Completed·RRadboud University Medical Center·Phase 1·NCT01740960·12 enrolled

Dementia1 trial

Delta-THC in Dementia

Completed·RRadboud University Medical Center·Phase 2·NCT01608217·50 enrolled

Chronic pain1 trial

Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)

Completed·UUniversity of Utah·Phase 1·NCT03215940·53 enrolled

3 more indications

Tics1 trial

Pharmacogenetics of Cannabinoid Response

Completed·YYale University·Phase 1·NCT00678730·72 enrolled

Impairment1 trial

Effects of Combined Alcohol and Cannabis on Young Drivers' Simulated Driving

Completed·CCentre for Addiction and Mental Health·Preclinical·NCT03106363·49 enrolled